TAK - TAKEDA PHARMACEUTICAL CO LTD

QQQ $ 454.82 $ 3.15 (0.7 %)

DIA $ 398.57 $ -1.85 (-0.46 %)

SPY $ 530.36 $ 0.61 (0.12 %)

TLT $ 91.26 $ -0.27 (-0.3 %)

GLD $ 225.37 $ 0.90 (0.4 %)

Previous Close

$ 13.28

Open

$ 13.32

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 13.27 - $ 13.32

52 Week Range

$ 12.77 - $ 16.47

Volume

594,399

Average Volume

Market Cap

22.5B

Beta (5Y Monthly)

$ 0.60

PE Ratio (TTM)

$ 9.42

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Takeda Canada Inc. Concludes Letter of Int...
05/16/2024 12:04:28

Takeda Canada Inc. ("Takeda") is pleased to announce that it has completed negotiations with the pan-Canadian Pharmaceu...

takedas-dengue-vaccine-gets-who-approval-eligible-for-un-procurement

Takeda's Dengue Vaccine Gets WHO Approval,...
05/15/2024 18:02:49

Takeda's dengue vaccine, Qdenga, gains WHO prequalification, enabling UN agency procurement. Approved in multiple countries...

Scilex Holding Announce Final Court Approv...
05/14/2024 13:03:58

Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")))), an innovative revenue-generating company focuse...

why-is-small-cap-alzheimers-focused-ac-immune-stock-trading-higher-on-monday

Why Is Small-Cap Alzheimer's-Focused AC Im...
05/13/2024 17:46:29

Unlocking hope for Alzheimer's with ACI-24.060. Takeda's agreement with AC Immune targets toxic forms of Abeta, potenti...

AC Immune And Takeda Sign Exclusive Option...
05/13/2024 10:06:21

japans-takeda-pharma-outlines-900m-overhaul-to-boost-growth-as-2023-profit-fall-over-50

Japan's Takeda Pharma Outlines $900M Overh...
05/09/2024 17:46:46

Takeda Pharmaceutical (NYSE: TAK) reveals fiscal year 2023 results & restructuring plan. Revenue up 5.9%, net profit down 5...

Takeda 2024 Outlook: Expects Revenue Of ¥ ...
05/09/2024 06:41:51

FY2024 Outlook (Billion yen) FY2024 FORECAST FY2024 MANAGEMEN...

Takeda Pharmaceutical FY23 Core EPS ¥484 D...
05/09/2024 06:34:35

HUTCHMED Announces Positive CHMP Opinion F...
04/26/2024 12:36:52

— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer reg...

Takeda Receives Positive CHMP Opinion For ...
04/26/2024 12:32:57

− If Approved in the European Union, Fruquintinib Will Be the First Novel Targeted Therapy for Metastatic Colorectal Cancer Reg...

neurocrine-biosciences-says-treatment-can-alleviate-several-symptoms-associated-with-depressive-disorder

Neurocrine Biosciences Says Treatment Can ...
04/23/2024 17:28:11

Neurocrine Biosciences reports Phase 2 data for NBI-1065845 in major depressive disorder. Results show significant improvement ...

Reported Earlier, Takeda Announces U.S. FD...
04/19/2024 06:27:28

ENTYVIO is Now Available in the U.S. in Both IV and Subcutaneous Administrations for Maintenance Treatment of Adults with Moder...

Takeda Announces Approval Of ADZYNMA Intra...
03/26/2024 12:02:24

cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening Acute Events and Debilitating Chronic SymptomsAD...

Takeda Announces U.S. FDA Approval Of Supp...
03/19/2024 16:21:44

− ICLUSIG Becomes the First and Only Targeted Treatment Approved in the U.S. for Frontline Ph+ Acute Lymphoblastic Leukemia (AL...

CENTOGENE Extends Strategic Partnership Wi...
03/19/2024 10:32:07

Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases...

Protagonist Therapeutics Closes Worldwide ...
03/18/2024 11:12:53

Takeda Announces Topline Results from Phas...
03/13/2024 12:06:56

Pre-Specified Interim Analysis Shows Positive Safety and Efficacy Results; Mezagitamab Safe and Well Tolerated Takeda Intend...

Takeda And Biological E. Limited Enter Str...
02/27/2024 07:30:26

Biological E. Limited (BE) to Manufacture Up to 50 Million Doses of QDENGA Per Year, Accelerating Takeda's Ability to Del...

fda-approves-takedas-eohilia-as-first-oral-treatment-for-inflammed-esophagus

FDA Approves Takeda's Eohilia As First Ora...
02/12/2024 17:17:23

Eohilia: FDA-approved oral therapy for EoE. Takeda's innovative 2mg/10mL stick packs available by February. Histologic remi...

FDA Approves Takeda's EOHILIA, The First A...
02/12/2024 13:00:58

— 12 Weeks of Treatment with EOHILIA May Address Significant Unmet Needs of Patients 11 Years of Age and Older— EoE Is a Chroni...